We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
22 May 2021 - 26 May 2021
Virtual Venue
25 May 2021 - 28 May 2021

Galectin-3 Predicts Cardiovascular Disease Risk in Diabetic Patients

By LabMedica International staff writers
Posted on 19 Oct 2020
Print article
Image: An ELISA kit for Galectin-3 which can predict cardiovascular events in patients with type-2 diabetes (Photo courtesy of Immuno-Biological Laboratories).
Image: An ELISA kit for Galectin-3 which can predict cardiovascular events in patients with type-2 diabetes (Photo courtesy of Immuno-Biological Laboratories).
Cardiovascular disease (CVD) is a general term for conditions affecting the heart or blood vessels. It's usually associated with a build-up of fatty deposits inside the arteries (atherosclerosis) and an increased risk of blood clots. Type 2 diabetes (T2D) can lead to early and severe atherosclerosis.

Galectin-3 (Gal-3) is also a member of the beta-galactoside-binding protein family that plays an important role in cell-cell adhesion, cell-matrix interactions, macrophage activation, angiogenesis, metastasis, and apoptosis. Galectin-3 is a novel prognostic biomarker with high predictive value for cardiovascular mortality and re-hospitalization in heart failure patients.

Medical scientists at the Fundacion Jimenez Diaz University Hospital (Madrid, Spain) studied 964 patients with coronary artery disease. They assessed baseline galectin-3, monocyte chemoattractant protein-1 (MCP-1) and N-terminal fragment of brain natriuretic peptide (NT-proBNP) plasma levels in the patients. Male patients were 75% in T2D group and 76.6% in the non-T2D group and mean age was 61.0 and 60.0 years, respectively. The team identified 232 patients with T2D. The patients were followed up for a median of 5.39 years.

The scientists reported that patients with T2D showed higher MCP-1(144 versus 133 pg/mL) and galectin-3 (8.3 versus 7.8 ng/mL) levels. Galectin-3 levels were associated with increased risk of the primary outcome in T2D patients (Hazard ratio [HR] = 1.57), along with a history of cerebrovascular events. NT-proBNP and MCP-1, but not galectin-3, were related to increased risk of the event in non-diabetic patients (HR = 1.21 and HR = 1.23 respectively), along with male sex and age. Galectin-3 was also the only biomarker that predicted the development of acute ischemic events and heart failure or death in T2D patients, while in non-diabetics MCP-1 and NT-proBNP, respectively, predicted these events.

The authors concluded that in patients with coronary artery disease (CAD), cardiovascular events are predicted by galectin-3 plasma levels in patients with T2D, and by MCP-1 and NT-proBNP in those without T2D. Galectin-3 predicts cardiovascular events in patients with type-2 diabetes. The study was presented at the European Society of Cardiology (ESC) Congress 2020 held virtually August 29 to September 1, 2020.

Related Links:
Fundacion Jimenez Diaz University Hospital

New
Gold Supplier
SARS-CoV-2 IgG ELISA Kit
NovaLisa SARS-CoV-2 IgG
New
Lateral Flow Test Reader
BSX READER
New
COVID-19 & Flu RT-PCR Kit
AccuPower RV1 Real-Time RT-PCR Kit
New
Gold Supplier
Integrated Immunoassay & Chemistry System
Dimension EXL with LM

Print article
Mayo Medical Laboratories
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Photograph of the novel capsule-based smell test (Photo courtesy of Queen Mary University of London)

A Novel Capsule-Based Smell Test for Diagnosis of Neurological and Respiratory Diseases

To aid in diagnosing diseases where loss of the sense of smell is a symptom, such as in chronic neurological conditions like Parkinson's and Alzheimer's diseases and in acute respiratory infections such... Read more

Pathology

view channel
Image: The Hamamatsu Photonics Nanozoomer 1 Digital Slide Scanner (Photo courtesy of University of Adelaide)

Genetic Background and Clinicopathologic Features Established for Adult-Onset Nephronophthisis

Nephronophthisis (NPH) is a genetic disorder of the kidneys which mainly affects children. It is classified as a medullary cystic kidney disease. The disorder is inherited in an autosomal recessive fashion... Read more

Industry

view channel
Image: DxA 5000 Fit (Photo courtesy of Beckman Coulter)

Beckman Coulter Becomes First Diagnostics Company to Offer Workflow Automation Specifically for Mid-Volume Laboratories

Beckman Coulter (Brea, CA, USA) has announced the global launch of the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.